Printer Friendly

Immunocore and Pulse Infoframe Partner with Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma.

M2 PHARMA-July 22, 2019-Immunocore and Pulse Infoframe Partner with Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma

(C)2019 M2 COMMUNICATIONS

- UK-based T cell receptor biotechnology company Immunocore Ltd and data aggregation and analytics company Pulse Infoframe, Inc have launched plans to support the first global patient registry in uveal melanoma, a rare and aggressive form of melanoma, which affects the eye, typically has a poor prognosis and for which there is no currently accepted optimal management or treatment, the companies said.

The insights gained through the academic registry will provide a more comprehensive understanding of the disease and may help to shape the way future research is conducted.

The registry will include institutions from across the US, UK and Australia, and is currently being developed by leaders in the field of uveal melanoma, including Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, Columbia University, US; Joseph Sacco, PhD, Clinical Senior Lecturer at the University of Liverpool and Honorary Consultant in Medical Oncology at Clatterbridge Cancer Centre, UK; and Anthony Joshua, MBBS, PhD, director of Cancer Services at St Vincent's Hospital and conjoint Associate Professor with the University of New South Wales, Australia

Research generated from the registry will examine risk factors, genetics, epidemiology, treatment cost-effectiveness and real-world outcomes from a database of patients with uveal melanoma.

The goal is to create a benchmark framework, or ecosystem, for collecting and assessing clinical outcomes, as well as providing necessary data for future genetic, sub-phenotype and biomarker research.

Enrolment into the registry is expected to begin in August at five sites in the US, three sites in the UK, and three sites in Australia.

Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye, typically has a poor prognosis and for which there is no currently accepted optimal management or treatment.

Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, with approximately 8,000 new patients diagnosed globally each year (1,600-2,000 cases/year in the US).

Up to 50% of people with uveal melanoma will eventually develop metastatic disease.

When the cancer spreads beyond the eye, only approximately 40% of patients will survive for one year.

Immunocore is a T cell receptor biotechnology company working to create first-in-class biological therapies that have the potential to transform patients' lives.

The company's primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development.

Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation.

Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US.

The company is privately held by a broad international investor base.

Focusing on rare disease and cancer, Pulse is a new style informatics company offering real-world insights and precision knowledge through dynamic analytics and data visualisation to accelerate time-to-value.

Pulse is headquartered in Canada, with offices in the United States, and the United Kingdom.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EUUK
Date:Jul 22, 2019
Words:525
Previous Article:Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of Darzalex.
Next Article:Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programmes from Novartis.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |